復星醫藥(02196.HK)擬成立合資海南復星商社醫療貿易
格隆匯 2 月 4日丨復星醫藥(02196.HK)公吿,於2021年2月4日,公司附屬公司天津謙達與復星商社就設立合資公司訂立股東協議,據此,合資公司註冊資本為人民幣5000萬元,其中,天津謙達擬以現金出資人民幣2550萬元,佔合資公司51%的股權,復星商社擬以現金出資人民幣2450萬元,佔合資公司49%的股權。合資公司海南復星商社醫療貿易有限公司成立後,將成為公司的附屬公司。
復星商社系一間於中國註冊成立的有限責任公司,系公司的控股股東復星高科技的附屬公司。其主營業務包括(其中包括)貨物、技術及食品進出口等。
訂立股東協議旨在通過設立合資公司,充分協同雙方資源,拓展並強化醫療物資供應鏈平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.